$GFLT
GenFlat Holdings, Inc. Stock $gflt

$gflt Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000165495423007357 Filed on May 30, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$0.00	$0.00	$1.884K
YoY Change	-100.0%		-93.49%
Cost Of Revenue			$0.00
YoY Change			-100.0%
Gross Profit			$1.884K
YoY Change
Gross Profit Margin			100.0%
Selling, General & Admin	$28.84K	$44.63K	$172.3K
YoY Change	-55.91%	325.86%	-77.16%
% of Gross Profit			9142.78%
Research & Development		$125.3K	$395.7K
YoY Change
% of Gross Profit			21003.87%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$28.84K	$44.63K	$172.3K
YoY Change	-55.91%	325.86%	-89.64%
Operating Profit	-$28.84K	-$174.1K	-$170.4K
YoY Change	-54.6%		-89.57%
Interest Expense	$2.427K	-$3.220K	$11.26K
YoY Change	-63.99%	-431.96%	-40.88%
% of Operating Profit
Other Income/Expense, Net	-$2.427K	-$760.00	$3.770K
YoY Change	-122.96%	-91.11%	-80.2%
Pretax Income	-$31.27K	-$47.85K	-$166.6K
YoY Change	-40.96%	-94.83%	-89.92%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$31.27K	-$47.85K	-$166.6K
YoY Change	-40.96%	-94.83%	-110.08%
Net Earnings / Revenue			-8842.68%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	21.30M shares	21.30M shares
Diluted Shares Outstanding			21.08M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.07K	$14.19K	$14.19K
YoY Change	-12.87%	-45.44%	-45.44%
Cash & Equivalents	$22.07K	$14.19K	$14.19K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$0.00
Prepaid Expenses	$477.0K
Receivables
Other Receivables
Total Short-Term Assets	$120.8K	$121.1K	$121.1K
YoY Change	-22.93%	-26.88%	-26.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.214K
YoY Change
Goodwill
YoY Change
Intangibles	$186.3K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$120.8K	$121.1K	$121.1K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$120.8K	$121.1K	$121.1K
YoY Change	-22.93%	-26.88%	-26.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$92.22K	$91.14K	$91.14K
YoY Change	-17.53%	18.75%	18.75%
Accrued Expenses	$5.659K	$3.368K	$3.370K
YoY Change	95.75%	-90.43%	-90.42%
Deferred Revenue
YoY Change
Short-Term Debt	$101.4K	$85.27K	$85.27K
YoY Change	-59.42%	-62.1%	-62.1%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$199.3K	$179.8K	$179.8K
YoY Change	-45.35%	-46.64%	-46.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$199.3K	$179.8K	$179.8K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$199.3K	$179.8K	$179.8K
YoY Change	-45.35%	-46.64%	-46.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.498M	-$3.466M
YoY Change	4.32%	5.05%
Common Stock	$21.30K	$21.30K
YoY Change	2.16%	2.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$78.55K	-$58.72K	-$58.72K
YoY Change
Total Liabilities & Shareholders Equity	$120.8K	$121.1K	$121.1K
YoY Change	-22.93%	-26.88%	-26.88%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$31.27K	-$47.85K	-$166.6K
YoY Change	-40.96%	-94.83%	-110.08%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$290.00	-$6.210K	-$51.51K
YoY Change	-99.14%	-86.03%	-81.65%
INVESTING ACTIVITIES
Capital Expenditures			$2.413K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$8.170K	$8.180K	$32.69K
YoY Change	0.0%	50.09%	-117.25%
Cash From Investing Activities	$8.171K	$8.180K	$32.69K
YoY Change	-0.01%	50.09%	-117.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$7.000K
YoY Change	-100.0%	-100.0%	-98.48%
NET CHANGE
Cash From Operating Activities	-$290.00	-6.210K	-$51.51K
Cash From Investing Activities	$8.171K	8.180K	$32.69K
Cash From Financing Activities	$0.00	0.000	$7.000K
Net Change In Cash	$7.881K	1.970K	-$11.82K
YoY Change	-1252.19%	-82.09%	30.73%
FREE CASH FLOW
Cash From Operating Activities	-$290.00	-$6.210K	-$51.51K
Capital Expenditures			$2.413K
Free Cash Flow			-$53.92K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Cash Cash	26013	usd
CY2023Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	106868	usd
CY2022Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	139553	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	0	usd
CY2022Q1	us-gaap	Notes Payable NotesPayable	175000	usd
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20853000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	21303	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3386255	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3466280	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-58722	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121060	usd
CY2023	hbr	Revenue Revenue	1884	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	114946	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1633157	usd
CY2021Q3	us-gaap	Unsecured Debt UnsecuredDebt	25000	usd
CY2022Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	179782	usd
CY2023Q1	us-gaap	Liabilities Liabilities	179782	usd
CY2022Q1	us-gaap	Liabilities Liabilities	336935	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21303000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	20853	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3107462	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3299684	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-171369	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165566	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20311058	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36612	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001796949
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--02-28
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20853000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21303000	shares
CY2021Q2	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.125	pure
CY2021Q3	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.12	pure
CY2021Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	Promissory Note will be due and payable two hundred seventy (270) days from June 10, 2021. Interest on the $50,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on June 10, 2021, until the principal amount and all accrued but unpaid interest shall have been paid
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-02-28
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56214
CY2023	dei	Entity Registrant Name EntityRegistrantName	Healthcare Business Resources Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3639946
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	718 Thompson Lane
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 108-273
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Nashville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37204
CY2023	dei	City Area Code CityAreaCode	615
CY2023	dei	Local Phone Number LocalPhoneNumber	856-5542
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	895500	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21303000	shares
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q1	us-gaap	Cash Cash	14192	usd
CY2022Q1	us-gaap	Advance Rent AdvanceRent	0	usd
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	50000	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	78271	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022	hbr	Revenue Revenue	28942	usd
CY2023	us-gaap	Revenues Revenues	1884	usd
CY2022	us-gaap	Revenues Revenues	28942	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57304	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	434858	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	319251	usd
CY2023	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	0	usd
CY2022	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	907990	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	172250	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1662099	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	11258	usd
CY2022	us-gaap	Interest Expense InterestExpense	19042	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3770	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-166596	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1652199	usd
CY2023	hbr	Earnings Per Common Share Basic And Diluted EarningsPerCommonShareBasicAndDiluted	-0.01
CY2022	hbr	Earnings Per Common Share Basic And Diluted EarningsPerCommonShareBasicAndDiluted	-0.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023	hbr	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	21076764	shares
CY2022	hbr	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	20311058	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21076764	shares
CY2022	hbr	Common Shares Issued For Cash Net Amount CommonSharesIssuedForCashNetAmount	86166	usd
CY2022	hbr	Common Shares Issued For Settlement Of Accounts Payable Amount CommonSharesIssuedForSettlementOfAccountsPayableAmount	38500	usd
CY2022	hbr	Common Shares And Warrants Issued For License Amount CommonSharesAndWarrantsIssuedForLicenseAmount	857990	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	384786	usd
CY2022	hbr	Captial Contributions Related Party CaptialContributionsRelatedParty	150000	usd
CY2022	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-1652199	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-171369	usd
CY2023	hbr	Common Shares Issued For Settlement Of Note Payable Related Party Amount CommonSharesIssuedForSettlementOfNotePayableRelatedPartyAmount	225000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	54243	usd
CY2023	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-166596	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-58722	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-166596	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1652199	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	54243	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	384786	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	14823	usd
CY2023	hbr	Impairment Expense ImpairmentExpense	0	usd
CY2022	hbr	Impairment Expense ImpairmentExpense	907990	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-15028	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	92660	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	78768	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-16785	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-14823	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51506	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-280655	usd
CY2023	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	0	usd
CY2022	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	-200000	usd
CY2023	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	32685	usd
CY2022	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	10447	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	32685	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-189553	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	175000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	225000	usd
CY2023	hbr	Proceeds From Notes Payable Related Party ProceedsFromNotesPayableRelatedParty	225000	usd
CY2022	hbr	Proceeds From Notes Payable Related Party ProceedsFromNotesPayableRelatedParty	50000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	50000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	150000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	86166	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	461166	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-11821	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9042	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26013	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35055	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14192	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26013	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	5135	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3666	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	38500	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	857990	usd
CY2023	hbr	Common Shares Issued For Settlement Of Note Payable Related Party CommonSharesIssuedForSettlementOfNotePayableRelatedParty	225000	usd
CY2022	hbr	Common Shares Issued For Settlement Of Note Payable Related Party CommonSharesIssuedForSettlementOfNotePayableRelatedParty	0	usd
CY2023	hbr	Expenses Paid With Senior Secured Convertible Credit Line ExpensesPaidWithSeniorSecuredConvertibleCreditLine	78271	usd
CY2022	hbr	Expenses Paid With Senior Secured Convertible Credit Line ExpensesPaidWithSeniorSecuredConvertibleCreditLine	0	usd
CY2023	hbr	Apitalization Of Rou Asset And Liability Operating apitalizationOfRouAssetAndLiabilityOperating	0	usd
CY2022	hbr	Apitalization Of Rou Asset And Liability Operating apitalizationOfRouAssetAndLiabilityOperating	14823	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1. NATURE OF BUSINESS AND GOING CONCERN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 9, 2019 (commencement of operations), Healthcare Business Resources, Inc. (“we”, “our”, the “Company”), a domestic corporation was organized in Delaware to provide consulting services to healthcare organizations. These services include management consulting related to sales, marketing, business development and advisory board function. The Company’s services are designed to help clients increase revenue, improve overall efficiency and effectiveness of their operations and grow strategically.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 5, 2021, HBR Pointclear, LLC, a Delaware limited liability company was incorporated. HBR Pointclear, LLC was formed to enter into an Option Agreement to Purchase Business Assets with PointClear Solutions, Inc.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 18, 2021, we and HBR Sub, Inc., a Delaware corporation and our wholly owned subsidiary entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”), with UserTech U.S. LLC, a Delaware limited liability company (“UPlus”) and UPlus Health, LLC, a Delaware limited liability company and a wholly-owned subsidiary of UPlus (“UPlus Health”). Pursuant to the Merger Agreement, and subject to the terms and conditions contained therein, HBR Sub, Inc. was merged with and into UPlus Health, with UPlus Health surviving the merger on the terms and subject to the conditions set forth in the Merger Agreement and certain ancillary agreements. UPlus Health is now our Company’s wholly owned subsidiary. UPlus helps companies across multiple industries with continuous innovation and market development through the implementation of its proprietary technology called the U+Method, which is a is a step-by-step product development methodology that focuses on front–loading the risky parts of product development before starting large buildouts (the “U+Method Technology”). UPlus has licensed to UPlus Health the U+Method Technology and related intellectual property for use in the health care and medical services industry (the “Medical Industry”), pursuant to the license attached to the Merger Agreement as Exhibit A (the “License Agreement”). UPlus and the Company believe that their individual capabilities and expertise could be combined to provide a unique integrated solution to clients in the Medical Industry; and UPlus’ post transaction participation in providing the anticipated integrated solution is set forth in the services agreement (the “Services Agreement”), a copy of which is set forth as Exhibit B to the Merger Agreement. The Company’s post transaction financial metrics plan for UPlus Health and the anticipated integrated solution is set forth in UPlus Health’s financial metrics plan (“Financial Metrics Plan”), a copy of which is set forth as Exhibit C to the Agreement. UPlus Health will be managed by the Company’s current management team.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In this filing, unless context requires otherwise, references to “we,” “our,” “us” and “our Company” refer to Healthcare Business Resources Inc., a Delaware corporation, and its subsidiaries HBR Pointclear, LLC, HBR Business Development, LLC and UPlus Health, LLC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> <strong><em>Liquidity and Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern twelve months from the issuance of these consolidated financial statements. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, or other third-party funding.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	907990	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	785000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1580000	shares
CY2023Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	106868	usd
CY2022Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	139533	usd
CY2021Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	25000	usd
CY2021Q2	hbr	Principal Amount PrincipalAmount	25000	usd
CY2021Q2	us-gaap	Unsecured Debt UnsecuredDebt	25000	usd
CY2021Q4	hbr	Principal Amount PrincipalAmount	25000	usd
CY2021Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	25000	usd
CY2021Q3	hbr	Principal Amount PrincipalAmount	25000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2688	usd
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	46000	shares
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	23000	shares
CY2022	hbr	Accredited Investors Total Common Stock AccreditedInvestorsTotalCommonStock	140000	shares
CY2022	hbr	Accredited Investors Total Consederation AccreditedInvestorsTotalConsederation	70000	usd
CY2022Q1	us-gaap	Share Price SharePrice	0.50
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	6834	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	86166	usd
CY2022	hbr	Equity Contributions Of Share EquityContributionsOfShare	150000	usd
CY2021Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	32000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.57
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1580000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.57
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1201474	shares
CY2022	hbr	Weighted Average Remaining Term WeightedAverageRemainingTerm	5.29
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	36000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	343000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-11000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-318000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-25000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-25000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	92900	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67900	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92900	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67900	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	442000	usd
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Description Of Lessor Leasing Arrangements Operating Leases DescriptionOfLessorLeasingArrangementsOperatingLeases	the Company entered into a sixteen month operating lease for office space
CY2023	hbr	Lease Expense LeaseExpense	4805	usd
CY2023Q1	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	7000	usd
CY2023Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	7000	usd
CY2021Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	50000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	50000	usd
CY2021Q3	us-gaap	Debt Instrument Description DebtInstrumentDescription	Promissory Note will be due and payable two hundred seventy (270) days from June 10, 2021. Interest on the $50,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on June 10, 2021, until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q2	us-gaap	Unsecured Debt UnsecuredDebt	50000	usd
CY2022Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	principal amount of $225,000 (the “$225,000 Promissory Note”). Stephen Epstein, the Company’s Chief Executive Officer, holds a Power of Attorney on behalf of Robert Epstein, who owns and controls RSET Investments QOZB, LLC. The principal amount of $225,000 plus all interest under the $225,000 Promissory Note will be due and payable on December 31, 2023. Interest on the $225,000 Promissory Note will accrue at the greater of rate of 2.0% per annum or the long-term adjusted applicable federal rates for the current month, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2022Q2	us-gaap	Unsecured Debt UnsecuredDebt	225000	usd
CY2022Q2	hbr	Promissory Note Converted PromissoryNoteConverted	225000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	530	usd
CY2022Q2	hbr	Promissory Note Converted Into Share PromissoryNoteConvertedIntoShare	450000	usd
CY2022Q3	hbr	Common Stock Issuance CommonStockIssuance	450000	usd

Files In Submission

Name	View Source	Status
0001654954-23-007357-index-headers.html	Edgar Link	pending
0001654954-23-007357-index.html	Edgar Link	pending
0001654954-23-007357.txt	Edgar Link	pending
0001654954-23-007357-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hbr-20230228.xsd	Edgar Link	pending
hbr_10k.htm	Edgar Link	pending
hbr_ex211.htm	Edgar Link	pending
hbr_ex311.htm	Edgar Link	pending
hbr_ex312.htm	Edgar Link	pending
hbr_ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
hbr-20230228_def.xml	Edgar Link	unprocessable
hbr-20230228_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
hbr-20230228_cal.xml	Edgar Link	unprocessable
hbr-20230228_lab.xml	Edgar Link	unprocessable
hbr_10k_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GFLT
GenFlat Holdings, Inc. Stock $gflt

2023 Q2 Form 10-K Financial Statement

#000165495423007357 Filed on May 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GFLT GenFlat Holdings, Inc. Stock $gflt

2023 Q2 Form 10-K Financial Statement

#000165495423007357 Filed on May 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GFLT
GenFlat Holdings, Inc. Stock $gflt